Genetic Study in Patients With Stage II or Stage III Colon Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00003833|
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : July 13, 2016
RATIONALE: Genetic studies may help in understanding the genetic processes that cause some types of cancer.
PURPOSE: Genetic trial to study certain genes of patients who have stage II or stage III colon cancer.
|Condition or disease||Intervention/treatment|
|Colorectal Cancer||Genetic: DNA stability analysis Genetic: gene mapping|
- Determine the adverse prognostic significance of 8p allelic imbalance (AI) in patients with colon cancer.
- Determine if patient prognosis is dependent on the region of 8p AI.
- Perform fine mapping studies to further localize the putative tumor suppressor gene(s) on 8p.
- Perform multicolor FISH to examine the role that 8p loss and 8q gain play in the prognosis of patients whose tumors exhibit 8p AI.
OUTLINE: Matched normal and tumor DNA is analyzed for 8p allelic imbalance with at least 8 markers: D8S262 and D8S1825 localized to 8p23, D8S254 and D8S261 at 8p22, D8S560 and D8S136 at 8p21, and D8S1820 and D8S283 at 8p12. Normal/tumor tissue pairs are used for fine mapping studies.
|Study Type :||Observational|
|Actual Enrollment :||598 participants|
|Official Title:||The Clinical and Pathological Significance of Allelic Imbalance of 8p in Patients With Colorectal Cancer|
|Study Start Date :||February 1999|
|Primary Completion Date :||August 2006|
|Study Completion Date :||August 2006|
Normal and tumor tissue pairs
Matched normal and tumor DNA is analyzed for 8p allelic imbalance with at least 8 markers: D8S262 and D8S1825 localized to 8p23, D8S254 and D8S261 at 8p22, D8S560 and D8S136 at 8p21, and D8S1820 and D8S283 at 8p12. Normal/tumor tissue pairs are used for fine mapping studies.
|Genetic: DNA stability analysis Genetic: gene mapping|
- overall survival [ Time Frame: Up to 10 years ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00003833
Show 59 Study Locations
|Study Chair:||Richard M. Goldberg, MD||Mayo Clinic|